ALEXANDRIA, Va. – Two prostate cancer studies – one examining the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide and one on plant-based diets and disease progression – will be highlighted in the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 800 abstracts that will be presented at the Symposium.
The 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18 in San Francisco, CA, and online, will bring together oncology professionals from around the globe for presentations and discussions surrounding the latest innovative findings in genitourinary cancer treatment, research, and care.
The majority of abstracts will be publicly released online at 5:00 PM (ET) on Monday, February 13, and the embargo will lift at that time. Late-Breaking Abstracts (LBAs) will be released at 7:00 AM (PT)/10:00 AM (ET) on their day of presentation at the meeting. The following abstracts will be highlighted in press releases as a part of the Press Program:
- TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract LBA17)
- Associations between plant-based diets and risk of disease progression in men with prostate cancer. (Abstract 392)
Reporters with approved ASCO media credentials will be able to access the embargoed meeting abstracts, press releases, and a tip sheet highlighting additional notable research beginning Wednesday, February 8.
Apply for/renew ASCO media credentials: Reporters with approved ASCO media credentials will be able to access embargoed press materials and view online presentations from the 2023 ASCO Genitourinary Cancers Symposium. Please visit ASCO’s Media Headquarters at mediahq.asco.org to request credentials or to ensure your credentials are up to date.
Attend the Symposium in person: Credentialed media who would like to attend the meeting in-person can submit a request to attend the meeting in person through Media Headquarters.
View the News Planning Team disclosures: https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/about-asco/pdf/2023-ASCO-GU-NPT-Disclosures.pdf
Founded in 1964, the American Society of Clinical Oncology, Inc. (the Society) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO® represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality and equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports the Society by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.